Publications by authors named "Greg Slatter"

Claim this Profile
I
Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors .
Terry Podoll, Paul G Pearson, Allard Kaptein, Jerry Evarts, Gerjan de Bruin, J Greg Slatter

J Pharmacol Exp Ther· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment.
Yan Xu, Raquel Izumi, Helen Nguyen, Anna Kwan, Howard Kuo, J Greg Slatter

J Clin Pharmacol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1).
Lu Zhang, Bill Poland, Michelle Green, Shekman Wong, J Greg Slatter

Xenobiotica· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Macrophage Inhibitory Cytokine-1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT-232) in Fed and Fasted Healthy Subjects.
Shekman Wong, Cecile Krejsa, Dana Lee, Anna Harris, Emilie Simard, J Greg Slatter

Clin Pharmacol Drug Dev· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Concentration-QTc and Cardiac Safety Analysis of the MDM2 Antagonist KRT-232 in Patients With Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia.
Adekemi Taylor, Dana Lee, Martine Allard, Bill Poland, J Greg Slatter

Clin Pharmacol Drug Dev· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices.
Xavier J H Pepin, Andrea J Moir, James C Mann, Natalie J Sanderson, Richard Barker, J Greg Slatter

Eur J Pharm Biopharm· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach.
Diansong Zhou, Terry Podoll, Yan Xu, Ganesh Moorthy, Karthick Vishwanathan, J Greg Slatter

CPT Pharmacometrics Syst Pharmacol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.
Helena Edlund, Sun Ku Lee, Marilee A Andrew, J Greg Slatter, Sergey Aksenov

Clin Pharmacokinet· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans.
Terry Podoll, Paul G Pearson, Jerry Evarts, Tim Ingallinera, Elena Bibikova, J Greg Slatter

Drug Metab Dispos· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Michael Wang, Simon Rule, Pier Luigi Zinzani, Andre Goy, Olivier Casasnovas, J Greg Slatter

Lancet· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment.
John P Gibbs, J Greg Slatter, Ogo Egbuna, Michelle Geller, Lisa Hamilton

J Clin Pharmacol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Biotransformation, and Excretion of [C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis.
Raju Subramanian, Xiaochun Zhu, M Benjamin Hock, Bethlyn J Sloey, Benjamin Wu, J Greg Slatter

Clin Pharmacokinet· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label study in healthy men to evaluate the risk of seminal fluid transmission of denosumab to pregnant partners.
Winnie Sohn, Edward Lee, Martin K Kankam, Ogo Egbuna, Graeme Moffat, J Greg Slatter

Br J Clin Pharmacol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intestinal and hepatic first-pass extraction of the 11β-HSD1 inhibitor AMG 221 in rats with chronic vascular catheters.
Qiuxia Gao, Robert E Kimura, Xiping Zhang, Joon Nam, Benny M Amore, J Greg Slatter

Xenobiotica· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshop.
Jane R Kenny, Maggie M Liu, Andrew T Chow, Justin C Earp, Raymond Evers, J Greg Slatter

AAPS J· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper.
Raymond Evers, Shannon Dallas, Leslie J Dickmann, Odette A Fahmi, Jane R Kenny, J Greg Slatter

Drug Metab Dispos· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity-based exposure comparisons among humans and nonclinical safety testing species in an extensively metabolized drug candidate.
Xiaochun Zhu, J Greg Slatter, Maurice G Emery, Molly R Deane, Anna Akrami

Xenobiotica· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of interleukin 1β (IL-1β) and IL-1β/interleukin 6 (IL-6) combinations on drug metabolizing enzymes in human hepatocyte culture.
Leslie J Dickmann, Sonal K Patel, Larry C Wienkers, J Greg Slatter

Curr Drug Metab· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Murine collagen antibody induced arthritis (CAIA) and primary mouse hepatocyte culture as models to study cytochrome P450 suppression.
Leslie J Dickmann, Helen J McBride, Sonal K Patel, Kent Miner, Larry C Wienkers, J Greg Slatter

Biochem Pharmacol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regiospecific and stereospecific triangulation of the structures of metabolites formed by sequential metabolism at multiple prochiral centers.
Robert J Greene, John A Davis, Raju Subramanian, Molly R Deane, Maurice G Emery, J Greg Slatter

Drug Metab Dispos· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222.
Robert J Greene, Hua Tu, John P Gibbs, J Greg Slatter

Xenobiotica· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture.
Leslie J Dickmann, Sonal K Patel, Dan A Rock, Larry C Wienkers, J Greg Slatter

Drug Metab Dispos· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.
Xia Yang, Bin Zhang, Cliona Molony, Eugene Chudin, Ke Hao, J Greg Slatter

Genome Res· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro metabolic activation of lumiracoxib in rat and human liver preparations.
Ying Li, J Greg Slatter, Zhoupeng Zhang, Yan Li, George A Doss

Drug Metab Dispos· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia.
Pek Yee Lum, Yudong D He, J Greg Slatter, Jeffrey F Waring, Nicollete Zelinsky

Genomics· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis